ImmunityBio vs Iovance Biotherapeutics
IBRX and IOVA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How IBRX and IOVA compare
ImmunityBio is the larger company, worth 2.3 times as much as Iovance Biotherapeutics ($8.8B against $3.8B).
ImmunityBio grew revenue faster over the last twelve months (193% versus 34.5% for Iovance Biotherapeutics).
Iovance Biotherapeutics keeps more of each dollar of sales as profit, with a net margin of −89.1% compared with −599% at ImmunityBio.
Iovance Biotherapeutics scores higher on the StockData Score (9 against 8 for ImmunityBio), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | IBRX | IOVA |
|---|---|---|
| Size and price | ||
| Market cap | $8.8B | $3.8B |
| Share price | $8.29 | $8.48 |
| Change, 1 year | 243% | 324% |
| Change, 5 years | −1.3% | −66.1% |
| Beta (5Y) | 1.61 | 1.23 |
| Employees | 691 | 975 |
| StockData Score | ||
| Total score | 8 | 9 (better) |
| Valuation score | 0 | 0 |
| Growth score | 2 | 2 |
| Performance score | 1 | 1 |
| Health score | 5 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 53.0× | 11.8× (better) |
| P/B | – | 5.2× |
| FCF yield | −3.3% (better) | −7.7% |
| Fair value | – | $4.11 |
| Margin of safety | – | −107% |
| Growth | ||
| Revenue growth (TTM) | 193% (better) | 34.5% |
| Revenue growth, 5Y average | 185% | – |
| Profitability | ||
| Gross margin | 99.3% (better) | 48.4% |
| Operating margin | −152% | −92.7% (better) |
| Net margin | −599% | −89.1% (better) |
| FCF margin | −174% | −91.2% (better) |
| Return on equity | – | −40.4% |
| Return on invested capital | – | −57.0% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Current ratio | 5.72 (better) | 4.35 |
| Altman Z-score | −7.44 | 8.14 (better) |
| Piotroski F-score | 5 (better) | 4 |
| Dividends and buybacks | ||
| Buyback yield | – | −7.6% |
| Shareholder yield | 0.00% (better) | −7.6% |
| Ownership | ||
| Held by institutions | 19.1% | 63.3% |
| Held by insiders | 75.3% | 0.39% |
| Insider net buying, 12 months | −$8.4M | – |
| Short interest, % of float | 47.3% | 14.4% |
Go deeper
- IBRX stock overview
- IBRX income statement
- IBRX valuation and score
- IOVA stock overview
- IOVA income statement
- IOVA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.